Myonal ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-020257-13-IT (EUCTR) | 30/07/2010 | 05/07/2010 | A pilot, prospective, randomized, open, blinded end point, phase II study of tolerability and efficacy of Eperisone in Amyotrophic Lateral Sclerosis - EPERISONE AND ALS | A pilot, prospective, randomized, open, blinded end point, phase II study of tolerability and efficacy of Eperisone in Amyotrophic Lateral Sclerosis - EPERISONE AND ALS | PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS MedDRA version: 9.1;Level: SOC;Classification code 10029205 | Trade Name: MYONAL*30CPR RIV 100MG INN or Proposed INN: EPERISONE Trade Name: LIORESAL*50CPR 10MG INN or Proposed INN: Baclofen | AZIENDA OSPEDALIERO-UNIVERSITARIA | NULL | Not Recruiting | Female: yes Male: yes | Phase 2 | Italy |